Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer.
The clinical and immunologic effects of a biosynthetic human leukocyte interferon, recombinant leukocyte A interferon (IFL-rA), are reported in eight patients with advanced cancer. Single escalating doses from 3 X 10(6) units to 198 X 10(6) units were given by intramuscular injection in a phase I study. Major toxic effects included pyrexia, fatigue, myalgia, and headache. Data on the effects of IFL-rA on lymphocyte subpopulations and peripheral blood mononuclear-cell surface beta 2-microglobulin are presented. Four of eight patients had objective tumor regression, indicating that further investigation of this biologically active material is warranted.
D003602:Cytotoxicity, Immunologic; D004274:DNA, Recombinant; D005221:Fatigue / Q000209:etiology; D005260:Female; D005334:Fever / Q000209:etiology; D006261:Headache / Q000209:etiology; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D007962:Leukocytes / Q000378:metabolism*; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D009369:Neoplasms / Q000628:therapy*; D001613:beta 2-Microglobulin / Q000032:analysis
D004274:DNA, Recombinant; D001613:beta 2-Microglobulin; D007372:Interferons